Celleron Therapeutics is a biopharmaceutical company specializing in the development of precision therapies and vaccines for various cancer indications. With a clinical and pre-clinical pipeline of innovative treatments, they are at the forefront of advancing cancer research. Led by a team of experienced professionals, including Professor Nick La Thangue, CEO and founder of Celleron Therapeutics, IngenOx is committed to translating cutting-edge cancer science into effective drugs.

The company's product portfolio includes Zabadinostat (CXD101), AT-101, and PCV-001, among others. These therapies aim to provide targeted and personalized treatments for cancer patients, helping to improve their outcomes and quality of life. With a strong focus on precision medicine, Celleron Therapeutics is dedicated to transforming the way cancer is treated, offering hope and progress in the fight against this devastating disease